Published in Metabolism on December 01, 1991
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med (2008) 4.85
Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab (2009) 2.20
The number of x chromosomes causes sex differences in adiposity in mice. PLoS Genet (2012) 2.02
The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev (2013) 1.93
A microarray analysis of sexual dimorphism of adipose tissues in high-fat-diet-induced obese mice. Int J Obes (Lond) (2010) 1.62
Sexual differences in the control of energy homeostasis. Front Neuroendocrinol (2009) 1.50
Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Why are we shaped differently, and why does it matter? Am J Physiol Endocrinol Metab (2008) 1.35
Minireview: the case for obesogens. Mol Endocrinol (2009) 1.33
Sex differences in the physiology of eating. Am J Physiol Regul Integr Comp Physiol (2013) 1.18
The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis. Mol Metab (2013) 1.17
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol (2009) 1.10
Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutr J (2007) 1.00
Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes (2014) 0.91
Efficacy of thigh volume ratios assessed via stereovision body imaging as a predictor of visceral adipose tissue measured by magnetic resonance imaging. Am J Hum Biol (2015) 0.85
Ovariectomy and overeating palatable, energy-dense food increase subcutaneous adipose tissue more than intra-abdominal adipose tissue in rats. Biol Sex Differ (2011) 0.83
Steatosis and steatohepatitis: complex disorders. Int J Mol Sci (2014) 0.83
Brown adipose tissue activation is inversely related to central obesity and metabolic parameters in adult human. PLoS One (2015) 0.83
Tobacco and metabolic syndrome. Indian J Endocrinol Metab (2012) 0.83
A model for estimating body shape biological age based on clinical parameters associated with body composition. Clin Interv Aging (2012) 0.82
Abdominal adiposity distribution in diabetic/prediabetic and nondiabetic populations: a meta-analysis. J Obes (2014) 0.81
Obesity and human papillomavirus infection in perimenopausal women. J Infect Dis (2013) 0.80
Membrane and nuclear estrogen receptor α collaborate to suppress adipogenesis but not triglyceride content. FASEB J (2015) 0.80
Effects of Hormone Replacement Therapy on Insulin Resistance in Postmenopausal Diabetic Women. Open Access Maced J Med Sci (2016) 0.79
G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci (2013) 0.79
Nonhuman primates and other animal models in diabetes research. J Diabetes Sci Technol (2012) 0.79
Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III. J Gastroenterol (2012) 0.79
Intake of dietary phytoestrogen and indices of antioxidant and bone metabolism of pre- and post-menopausal Korean women. Nutr Res Pract (2007) 0.79
Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease. Front Aging Neurosci (2015) 0.78
Morphological and metabolic determinants of nonalcoholic fatty liver disease in obese youth: a pilot study. BMC Res Notes (2013) 0.78
Endocrine Disruptors and Obesity. Curr Obes Rep (2017) 0.77
Sex and sex steroids: impact on the kinetics of fatty acids underlying body shape. Horm Mol Biol Clin Investig (2014) 0.77
Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program. Obesity (Silver Spring) (2013) 0.76
Association of Mid-Life Changes in Body Size, Body Composition and Obesity Status with the Menopausal Transition. Healthcare (Basel) (2016) 0.76
Linkage analysis of obesity phenotypes in pre- and post-menopausal women from a United States mid-western population. BMC Med Genet (2010) 0.75
Long working hours and overweight and obesity in working adults. Ann Occup Environ Med (2016) 0.75
Association Between Obesity and Migraine in Women. Curr Pain Headache Rep (2017) 0.75
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Bacterial genome sizes determined by DNA renaturation studies. J Gen Microbiol (1970) 5.86
Serological cross-reactions between Mycoplasma genitalium and Mycoplasma pneumoniae. J Clin Microbiol (1984) 3.15
Genome size of mycoplasmal DNA. Nature (1969) 2.86
Prediction of rapid bone loss in postmenopausal women. Lancet (1987) 2.76
Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J (1973) 2.60
Bone-density measurement. Lancet (1992) 2.38
Letter: Anticonvulsant hypomagnesaemia. Br Med J (1974) 2.30
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ (1991) 2.12
Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest (1980) 2.04
Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med (1987) 2.03
Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int (2002) 2.01
Complete DNA sequence of yeast chromosome II. EMBO J (1994) 1.97
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem (1994) 1.93
The sequence of 16S rRNA from Mycoplasma strain PG50. DNA (1985) 1.91
Circular, repetitive DNA in yeast. Biochim Biophys Acta (1972) 1.88
A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum (2004) 1.87
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med (1985) 1.81
Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet (1981) 1.81
Catalysis of DNA reassociation by the Escherichia coli DNA binding protein: A polyamine-dependent reaction. J Mol Biol (1977) 1.73
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Bone mineral content in the forearm measured by photon absorptiometry. Principles and reliability. Scand J Clin Lab Invest (1975) 1.65
Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int (2003) 1.63
Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 1.61
Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop Relat Res (1982) 1.59
Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis (1985) 1.54
Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem (1998) 1.51
The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric (2006) 1.50
Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage (2008) 1.50
Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med (2006) 1.49
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Accuracy of measurements of body composition by dual-energy x-ray absorptiometry in vivo. Am J Clin Nutr (1993) 1.48
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone (1996) 1.45
Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res (1990) 1.45
Postmenopausal osteoporosis: therapeutic options. Climacteric (2005) 1.45
Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med (1993) 1.44
Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period. Osteoporos Int (1991) 1.42
Circular DNA molecules controlling synthesis and transfer of the surface antigen (K88) in Escherichia coli. J Gen Microbiol (1972) 1.41
Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41
Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol (1991) 1.41
Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis (2003) 1.40
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand (1981) 1.40
Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40
Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res (1991) 1.37
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers (2009) 1.37
Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab (1987) 1.36
Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ (1989) 1.34
Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int (2006) 1.33
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab (1988) 1.33
Mechanism of circadian variation in bone resorption. Bone (2002) 1.33
Effect of puberty on rates of bone growth and mineralisation: with observations in male delayed puberty. Arch Dis Child (1979) 1.31
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30
Efficient identification of postdischarge surgical site infections: use of automated pharmacy dispensing information, administrative data, and medical record information. J Infect Dis (1999) 1.29
Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) (1989) 1.29
Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet (1978) 1.29
Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes (1984) 1.28
Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) (1979) 1.28
Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism (1995) 1.28
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ (1992) 1.27
Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. Clin Rheumatol (1984) 1.27
Calcium supplementation and postmenopausal bone loss. Br Med J (Clin Res Ed) (1984) 1.27
Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care (1995) 1.26
The transplanted parathyroid gland: evaluation of cryopreservation and other environmental factors which affect its function. Surgery (1974) 1.25
Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone (2000) 1.24
Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol (Oxf) (1982) 1.24
Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy (2009) 1.24
Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab (1995) 1.23
Influence of menopause on serum lipids and lipoproteins. Maturitas (1990) 1.23
Bone changes occurring spontaneously and caused by estrogen in early postmenopausal women: a local or generalised phenomenon? Br Med J (Clin Res Ed) (1986) 1.22
Usefulness of regional bone measurements in patients with osteoporotic fractures of the spine and distal forearm. J Nucl Med (1987) 1.21
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med (1990) 1.20
The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum (1985) 1.19
Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. Clin Chim Acta (1982) 1.19
Comparison of single- and dual-photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med (1985) 1.19
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage (2006) 1.19
Long-term reproducibility of bone mineral content measurements. Scand J Clin Lab Invest (1977) 1.19
Body composition and calcium metabolism in adult treated coeliac disease. Gut (1991) 1.18
Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res (1999) 1.18
Lithium, hypercalcemia, hypermagnesemia, and hyperparathyroidism. Lancet (1976) 1.17
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
The mineral content in bone. Measured by means of 27.5 keV radiation from 125I. Acta Radiol Suppl (1972) 1.16
Separation of healthy and early osteoarthritis by automatic quantification of cartilage homogeneity. Osteoarthritis Cartilage (2007) 1.16
Management of hypersensitivity reactions to iodinated contrast media. Allergy (2005) 1.16